Literature DB >> 11528386

PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients.

L F Barcellos1, S Caillier, L Dragone, M Elder, E Vittinghoff, P Bucher, R R Lincoln, M Pericak-Vance, J L Haines, A Weiss, S L Hauser, J R Oksenberg.   

Abstract

A C-->G nucleotide transition in exon 4 of PTPRC (encoding protein-tyrosine phosphatase receptor-type C, also known as CD45) was recently reported to be genetically associated with the development of multiple sclerosis (MS). We performed an extensive evaluation of this polymorphism using large family-based and case-control comparisons. Overall, we observed no evidence of genetic association between the PTPRC polymorphism and MS susceptibility or disease course.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11528386     DOI: 10.1038/ng722

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  19 in total

Review 1.  New approaches to investigating heterogeneity in complex traits.

Authors:  R Bomprezzi; P E Kovanen; R Martin
Journal:  J Med Genet       Date:  2003-08       Impact factor: 6.318

2.  PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients.

Authors:  Eleonora Cocco; Maria Rita Murru; Cristina Melis; Lucia Schirru; Elisabetta Solla; Marina Lai; Marcella Rolesu; Maria Giovanna Marrosu
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 3.  Regulatory polymorphisms underlying complex disease traits.

Authors:  Julian C Knight
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

4.  Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection.

Authors:  R Dawes; B Hennig; W Irving; S Petrova; S Boxall; V Ward; D Wallace; D C Macallan; M Thursz; A Hill; W Bodmer; P C L Beverley; E Z Tchilian
Journal:  J Med Genet       Date:  2006-02-27       Impact factor: 6.318

5.  A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31.

Authors:  Bo Johanneson; Guadalupe Lima; Jenny von Salomé; Donato Alarcón-Segovia; Marta E Alarcón-Riquelme
Journal:  Am J Hum Genet       Date:  2002-10-08       Impact factor: 11.025

6.  Unusual case presentations associated with the CD45 C77G polymorphism.

Authors:  E Z Tchilian; J Gil; M L Navarro; E Fernandez-Cruz; H Chapel; S Misbah; B Ferry; H Renz; R Schwinzer; P C L Beverley
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 7.  Protein tyrosine phosphatases in lymphocyte activation and autoimmunity.

Authors:  Inmoo Rhee; André Veillette
Journal:  Nat Immunol       Date:  2012-04-18       Impact factor: 25.606

Review 8.  CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans.

Authors:  Tara Stanton; Sally Boxall; Andrea Bennett; Pontiano Kaleebu; Christine Watera; Jimmy Whitworth; Neil French; Ritu Dawes; Adrian V S Hill; Walter Bodmer; Peter C L Beverley; Elma Z Tchilian
Journal:  Immunogenetics       Date:  2004-04-01       Impact factor: 2.846

Review 9.  Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity.

Authors:  Stephanie M Stanford; Novella Rapini; Nunzio Bottini
Journal:  Immunology       Date:  2012-09       Impact factor: 7.397

10.  Altered CD45 isoform expression in C77G carriers influences cytokine responsiveness and adhesion properties of T cells.

Authors:  A Windhagen; D Sönmez; H T Hornig-Do; A Kalinowsky; R Schwinzer
Journal:  Clin Exp Immunol       Date:  2007-09-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.